Nabsys 2.0, LLC (Nabsys), a pioneer in electronic genome mapping technology, today presented new findings that highlight the ...

OncoNano Medicine, Inc. ("OncoNano") today announced a late-breaking research poster presentation at the EORTC-NCI-AACR ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the European ...

Results from the largest cohort of children who received a gene therapy for a rare immunodeficiency condition have shown the long-term safety and efficacy of the curative treatment, in a study led by ...

Depending on the setting, the ability of a crucial bacterium in biotechnology—Agrobacterium tumefaciens—to transfer its DNA ...

October 14, 2025-- Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced an upcoming poster ...

A new gene therapy approach aimed at protecting people with type 1 diabetes from developing diabetic kidney disease—a serious ...

OVATION 3 is IMUNON’s pivotal Phase 3 study of IMMN-001, an IL-12 gene-mediated immunotherapy, in women with advanced stage epithelial ovarian cancer. The study is supported with unprecedented overall ...

MIT scientists have found a way to make gene editing far safer and more accurate — a breakthrough that could reshape how we ...

When political expression enters the workplace, it threatens productivity, relationships and company reputation — that's why ...